Over the last three decades, a surge in research into the inflammatory pathophysiology of atherosclerosis has highlighted an array of cytokines and other inflammatory mediators associated with underlying inflammatory burden. The ability to identify and simultaneously measure multiple cytokines in peripheral blood highlights their potential as biomarkers of atherosclerosis. This has prompted much research in vascular medicine to identify the 'at-risk' groups for atherostenotic or atheroaneurysmal disease. This review is compiled with similar intentions and aims to discern the relevant evidence for cytokine profiling in peripheral arterial disease (PAD), where such information is lacking, while providing a holistic overview of cytokine interactions in atherosclerosis. This is pertinent given that cytokine profiles from coronary artery disease and aortic aneurysm studies cannot be directly extrapolated to PAD due to differences in inflammatory environments that exist in these conditions. Whilst plaque morphology and blood rheology play an important role in the cardiac manifestations of atherosclerosis, tissue thrombogenecity is very important in PAD. Further, cytokines act in concert rather than in isolation in a disease process, and no single cytokine in a cross-sectional model is able to serve as an absolute screening marker. Thus, it is essential to understand the regulation of cytokine production in atherosclerosis prior to evaluating the viability and merits of a multimarker approach for clinical risk stratification in PAD.
Introduction
Atherosclerosis remains the leading cause of morbidity and mortality in the developed world. Chronic inflammation is the hallmark of atherosclerosis. It affects every step of the atherosclerotic process, from emergence of the fatty streak 1 -the first identifiable lesion of atherosclerosis -to endothelial activation and subsequent vascular dysfunction and vessel occlusion. More specifically, its clinical manifestations in the distal aorta and arteries in the legs are referred to as peripheral arterial disease (PAD) and affects about 4.5% of the population above 40 years of age, increasing to 14.5% above 70 years of age. 2 The PARTNERS study, which was a multi-centre, cross-sectional study conducted in 25 cities and 350 primary care practices throughout the United States, reported a PAD prevalence rate of 29%. 3 Although PAD is not directly life threatening, affected patients have a higher risk of morbidity and mortality due to generalized atherosclerosis. It remains largely under-diagnosed, 3 with an estimated six asymptomatic patients for every known symptomatic patient. 4 The inflammatory phenomenon related to atherosclerosis has been extensively studied over the past two decades and a variety of inflammatory and immunological mediators have been identified which positively correlate with the underlying disease load. They regulate every stage of the inflammatory cascade, from endothelial activation to the adhesion of inflammatory cells and platelets, and subsequent remodelling of the internal vascular environment.
Cytokines are key regulatory glycoproteins allied to inflammatory/immunological processes which modulate all aspects of vascular inflammation by altering the proliferation, differentiation and function of an extensive array of cell types. They are intimately associated with atherogenesis and modulate plaque morphology and stabilization. Atheromatous plaque consists of a lipid core covered by a fibrotic cap on the luminal surface. Integrity of the fibrous cap depends on the balance between the smooth muscle cell (SMC) proliferation and migration, and matrix metalloproteinase (MMP)-induced degradation of the extracellular matrix (ECM). The local balance between the pro-and anti-inflammatory cytokines is instrumental in determining structure of the fibrous cap and SMC degradation, thereby influencing plaque stability. Cytokines were initially discovered about 50 years ago through their mitogenic and chemotactic effects on lymphocyte and monocyte populations. Although initial research focused more on pro-inflammatory cytokines [T-helper cell (Th) 1 ] in relation to disease progression, it is the imbalance between pro-and antiinflammatory (Th 2 cytokines) that is emerging to be pivotal to this process. Th 2 cytokines, which were initially considered to be protective, have now been found to be strongly associated with human abdominal aortic aneurysm (AAA) development. By comparison, stenotic atherosclerotic lesions are associated with Th 1 responses. 5 Cytokines act by binding to specific receptors, an interaction which has clarified their involvement in atherosclerosis and highlighted potential new avenues of therapeutic intervention. There are over 200 cytokines cloned to date and various classification systems have been used for the purpose of their categorization, although no single system has proven sufficiently comprehensive to be considered as a standard format. The difficulty in categorizing cytokines has largely related to the complexity and overlap of their biological roles. Structurally, cytokines can be classified into nine different families (Table 1) : the interleukin (IL)-1, IL-2/IL-4, IL-6/IL-12, interferon (IFN), tumour necrosis factor (TNF), chemokines, IL-10, transforming growth factor ␤ (TGF-␤) and IL-17 families. This system will be used for discussing representative cytokines from each family in the context of atherosclerosis and PAD for the purpose of this review. In this respect, IL-17 is potentially pro-atherogenic because of its role in augmenting the expression of pro-inflammatory cytokines such as IL-6 from macrophages. Although it has recently been found to be associated with unstable angina, 6 there is no direct evidence implicating it with atherosclerosis and its family will therefore not be discussed as a part of this review.
The interleukin (IL)-1 family

IL -1 and IL -1 receptor antagonist
The IL-1 cytokine family comprises four main members: IL-1␣, IL-1␤, IL-1 receptor antagonist (IL-1ra) and IL-18. Although IL-1 can upregulate host defences and act as an immunoadjuvant, the family is primarily considered to be pro-inflammatory. 7 IL-1 was one of the first cytokines to be implicated in vessel wall inflammation in atherosclerosis, and in facilitating early lesion formation. Its effect on leukocyte recruitment and transmigration allows it to maintain a proinflammatory milieu once the inflammation has been initiated. Increased IL-1 levels have also been associated with an increased tendency for plaque rupture. 8 The only member of this family with paradoxical properties is IL-1ra, a naturally occurring cytokine antagonist, which plays an anti-inflammatory role in regulating IL-1 function. In this respect, IL-1ra injections in rheumatoid arthritis patients can reduce inflammatory joint destruction. 9 However, no similar therapeutic approaches have been determined for this cytokine in cardiovascular medicine. IL-1ra has been shown to be up-regulated in atherosclerosis and to correlate with the clinical stage of the disease in a small cohort of PAD patients in a number of studies. 10 
IL-1␤
␤ IL-1␤ plays a significant role in inflammation, as demonstrated by studies on IL-1␤-deficient mice: these animals failed to exhibit an acute phase response, remained apyrexic and exhibited no rise in circulating IL-6 levels when receiving an inflammatory stimulus. 12 IL-1␤ has been implicated in enhancing expression of cell adhesion molecules on the endothelial surface and has consequently been deemed to be pro-atherogenic. 13 Taken together, these findings highlight the potential role of IL-1␤ in PAD through its eliciting of IL-6 production, an independent predictor of PAD progression in the Edinburgh artery study. 14 However, while IL-1␤ levels have been found to be increased in the pericardial fluid of patients with unstable angina, 15 plasma levels of IL-1␤ have not been found to be indicative of PAD. 10, 11 IL-18 IL-18 is a more recently identified member of the IL-1 family, initially identified for its role in inducing IFN-␥ production. IL-18 is an immunomodulator and does not fall neatly into the typical Th 1 :Th 2 dichotomy, inasmuch as it can induce either of these responses depending on the prevailing immunological environment. Like many cytokines, it acts synergistically with other similar proteins and mediators in order to potentiate its effects. Experimental evidence from studies using apo E -/-mice confirms IL-18 to be atherogenic. While exogenous administration of IL-18 in these mice enhances atherosclerotic lesions, 16 there is conversely a reduction in atherosclerosis by inhibiting IL-18. 17, 18 IL-18 has a bearing on the progression of human atherosclerotic plaques, particularly in relation to their stability. 19 Furthermore, IL-18 genetic polymorphisms have been associated with clinical outcome in coronary artery disease. 20 Although IL-18 is considered to be a predictor of future cardiovascular risk, 21 there are currently no data to indicate that IL-18 levels are elevated in association with PAD.
The IL-2 family
IL-2
The IL-2 family comprises of four representative members: IL-2, IL-4, IL-5 and granulocyte-monocyte colony-stimulating factor (GM-CSF). The most noteworthy action of IL-2 relates to its mitogenic effects on T lymphocytes in response to antigenic stimulation, including the generation of both cytotoxic and suppressor T cells. However, despite extensive attempts to fully understand the actions and signalling pathways of IL-2, the nature of its pleiotropic effects on an array of cell types remains elusive. Although IL-2 is detected in atheromatous lesions, its precise role in vascular plaque formation remains poorly understood. Indeed, although IL-2 levels are elevated in the blood and in the aortic tissue of patients with aortic aneurysm disease, the rate of aneurysm expansion appears to depend on the overall Th 1 :Th 2 cytokine imbalance 22 in favour of Th 2 cytokines. Although studies to date have failed to address the role of IL-2 in PAD, this cytokine is nevertheless integral to vascular inflammatory processes and promotes the maintenance and function of naturally occurring regulatory T cells, mostly at the transcriptional levels both in vivo and in vitro. 23
IL-4
Since IL-4 is produced by Th 2 cells, it has been proposed to play a protective role in atherosclerosis. This is supported by phenomena such as IL-4-induced suppression of pro-atherogenic cytokines (e.g. IL-12) and inhibition of SMC proliferation and macrophage adhesiveness. 24 However, IL-4 has been found to cause an increased expression of P-selectin, 25 vascular cell adhesion molecule-1 (VCAM-1), and MMP-1 and 12, which are implicated in aortic aneurysm formation. IL-4 responses have also been found to predominate in aortic aneurysms both in animal models and human studies. 26 More recent studies also indicate that IL-4 causes differential IL-12 expression, 27 rather than a distinct inhibitory effect, as was previously noted. Although there is some evidence that IL-4 levels are elevated in acute coronary syndrome in comparison to stable disease, 28 no definitive involvement of IL-4 has been implicated in the severity of manifestation of PAD to date; small cross-sectional studies reflect non-significant variations in IL-4 levels in association with PAD (which are very low overall). This may also be explained by a shift in the Th 1 :Th 2 balance in favour of a Th 1 milieu in atherostenotic disease, as detailed above.
GM-CSF
GM-CSF stimulates the proliferation, differentiation and function of multiple myeloid cells including neutrophils, monocytes/macrophages, eosinophils and dendritic cells. Its main clinical use is in mobilizing peripheral blood stem cells in myelosuppressive disorders, drug-induced agranulocytosis and immunodeficiency syndromes. It has been implicated in atherosclerosis because a decrease in plasma cholesterol levels has been observed in patients receiving GM-CSF for haematological disorders. These findings are mirrored by GM-CSF treatment of Watanabe heritable hyperlipidaemic rabbits, which also exhibit a significant decrease in total cholesterol levels for up to 2 weeks following cessation of recombinant GM-CSF administration. 29 Related leporine studies 30 have also indicated that GM-CSF can prevent the progression of atherosclerotic plaques. After 7.5 months of GM-CSF treatment, a 45% reduction in the atherosclerotic lesion of the aortic arch was noted along with a reduction in intimal thickening compared to untreated animals.
GM-CSF has traditionally been considered a proinflammatory cytokine based on in vivo and in vitro studies using lipopolysaccharide challenge. 31 However, this distinction becomes blurred in atherosclerosis, 32 where GM-CSF has been shown to confer some protective effects. 32 GM-CSF is also a potential marker of chronic and severe inflammation (as opposed to acute responses) as its levels become more resistant to suppression by inhibitors such as glucocorticoids in this situation. 33 Recently, there has been renewed interest in the role of GM-CSF in atherosclerosis because of its angiogenic properties. Following pioneering studies in rodents, subcutaneous GM-CSF administration has been shown to promote collateral flow in the coronary circulation, with a decrease in ECG signs of myocardial ischaemia. 34 Unfortunately, these results have not been reproduced in PAD patients 35 (START trial), despite beneficial effects being seen in porcine models of PAD. 36 Although there are currently no data supporting the role of GM-CSF as a cytokine signature of PAD, our preliminary studies in this area have nevertheless indicated that there is a trend for GM-CSF levels to be marginally higher in claudicants (present authors, unpublished).
IL-7
IL-7 was first discovered almost two decades ago for its role in promoting the growth of B-cell precursors in bone marrow culture systems. 37 This cytokine is discussed under the IL-2 family because its receptor shares the common ␥ chain with other IL-2 family members. IL-7 is now an established regulator of T-cell homeostasis in both thymic and extra-thymic tissues, 38 and has more recently been implicated as a proinflammatory factor in atherosclerosis, with higher levels detected in patients with unstable angina, compared to stable angina and controls. 39 This study also revealed that aspirin causes a significant decline in both spontaneous and stimulated IL-7 release from platelets in vitro. However, only one study has investigated IL-7 levels in relation to PAD (as a subgroup of an atherosclerotic cohort), and revealed that IL-7 was undetectable in these patients. 40 The IL-6/IL-12 family
IL-6
This pro-inflammatory cytokine is probably the most consistent biomarker of PAD identified thus far ( Table 2) . The Edinburgh artery, 14 InCHIANTI 11 and MESA 45 studies have all individually established its role as an independent predictor of PAD in community screening, irrespective of ethnicity. Furthermore, IL-6 has been found to be associated with PAD severity 41 and its genetic polymorphisms have been implicated in increasing susceptibility of type 2 diabetics to develop PAD. 44 IL-6 enhances cell adhesion molecule (CAM) expression by endothelial and smooth muscle cells, and enhances the production of acute phase reactants such as C-reactive protein (CRP) and TNF-␣ by the hepatocytes. As such, plasma IL-6 concentrations in healthy populations correlate with metabolic and inflammatory factors such as TNF-␣ and CRP, which are considered relevant to atherosclerotic progression, 53 and in the case of the latter, associated with increased risk of death from cardiovascular pathology. More specifically, IL-6 has a positive feedback interaction with intimal cells and macrophages to further stimulate its own production, along with that of IL-8 and monocyte chemoattractant protein (MCP)-1. IL-6 also increases leucocyte recruitment into the atherosclerotic plaque by stimulating chemokine release from the endothelium and by enhancing expression of intercellular adhesion molecule-1 (ICAM-1) by the smooth muscle cells. 54 It may also stimulate smooth muscle cells to evolve into foam cells, 55 thereby adversely effecting plaque morphology.
IL-12
IL-12 (p70) is a heterodimeric protein, composed of a heavy chain (p40) and a covalently associated light chain (p35). The expression of each of these subunits is independently regulated, but biologically active IL-12 can only be produced by cells with the capacity to produce both light and heavy chains. The primary function of IL-12, as proven in both animal models and humans, is the induction and sustenance of Th 1 responses to infection/antigen exposure by facilitating the secretion of cytokines such as IL-2, IFN-␥, IL-18 and an array of chemokines. While IL-12 has been implicated in the progression of atherosclerosis, functional blockade of endogenous IL-12 production can reduce atherogenesis in LDL receptor-deficient mice and improve plaque stability. 56 Immunohistochemical studies have also revealed an increased presence of IL-12 (p70) in human atherosclerotic plaques compared to normal arteries, 57 thereby supporting its role in promoting plaque inflammation in human coronary arteries by enhancing local T-cell recruitment. 58 While raised IL-12 levels in the coronary arteries in vivo are a feature of unstable angina, 59,60 no evidence is available regarding IL-12 profiles in PAD to date.
IL-12 acts synergistically with IL-18 to elicit Th 1 responses, as well as facilitating the release of IFN-␥ by Th 1 cells. IFN-␥ and IL-12 act in combination to promote Th 1 function too, with IFN-␥ further up-regulating IL-12 production. Paradoxically, IL-12 also regulates Th 2 responses by inducing the production of IL-10 and IL-13 while inhibiting IL-4 and IL-5 production. 27 This is part of a protective negative feedback mechanism, which comes into play in chronic inflammatory states in particular. IL-10 causes feedback inhibition of IL-12 57 while IL-4 has a similar effect on IFN-␥. The interaction between IL-4 and IL-12 is more complex: although initial reports indicated that IL-4 inhibited IL-12, recent evidence suggests that IL-4 has more subtle effects by inducing differential IL-12 expression rather than overall inhibition. 61 Thus, although IL-12 enhances IFN-␥ production, it also concomitantly enhances production of anti-inflammatory cytokines that limit IFN-␥ production, highlighting the complex network system in which cytokines operate. Understanding these interactions is pivotal to clarifying the inflammatory pathophysiology allied to atherosclerotic progression and revealing the prognostic potential of cytokines in PAD (Figure 1 ).
The interferon (IFN) family
IFN-␥ ␥
IFN-␥ is a pleiotropic pro-inflammatory cytokine primarily secreted by T lymphocytes and natural killer cells following activation by immune and inflammatory stimuli. It induces expression of ICAM-1, VCAM-1 and selectins by endothelial and smooth muscle cells, and promotes leucocyte adhesion at the site of the vascular lesion. 62 As outlined, it acts in concert with IL-12 and IL-18 to promote atherosclerosis. 63 More specifically, a reduction in atherosclerosis was also noted in cholesterol-diet fed mice in the absence of IFN-␥. 64 By contrast, IFN-␥ has also been associated with a reduction in atherosclerotic lesion size in apo E -/-mice. 65 IFN-␥ is intimately related to plaque morphology, with enhanced expression reported in unstable plaques. 66 This relationship with atherosclerotic lesions has been consistently reproduced in clinical samples as well as rodent atherosclerosis models. There is also an associated rise in pro-inflammatory cytokines such as MCP-1 and macrophage inflammatory protein (MIP)-1␣ and ␤ within the plaque. IFN-␥ potentially destabilizes Fiotti et al 10 16 Significant increase in TNF-␣R1 and 2, IL-6 and IL-1ra in PAD 1999
Kirk et al 52 26 Significantly elevated IL-8 at rest and post-exercise in PAD VEGF, vascular endothelial growth factor; CLI, critical limb ischaemia; hsCRP, high-sensitivity C-reactive protein; sTNF-␣R1 and 2, soluble TNF-␣ receptors 1 and 2; OPG, osteoprotegerin; sVCAM, soluble vascular cell adhesion molecule.
Other abbreviations can be found in the text.
the fibrous cap by inhibiting SMC proliferation as well as IL-1␤ and TGF-␤-mediated collagen synthesis. However, there is an ambivalent element to its otherwise pro-atherogenic role through its attenuation of constitutive and inducible MMP expression within the plaque. 67 In addition, it regulates foam cell apoptosis within the lipid core of the plaque. 68 It is, therefore, difficult to determine whether IFN-␥ forms unstable plaque from the outset or if there is a shift in the plaque modulation mechanism of IFN-␥ with advanced atherosclerosis, causing plaque instability at a later stage. Although IFN-␥ has not been investigated in the context of PAD, its profiles should be studied in relation to IL-12, IL-4 and IL-10 levels given what has been discussed above ( Figure 1B) .
The tumour necrosis factor (TNF) family
TNF-␣ ␣ TNF-␣ is a pro-inflammatory prototype member of this family. Initially identified as an anti-tumour agent, it is now recognized as a pleiotropic cytokine with multiple, dose-dependent actions on both local and systemic inflammation. TNF-␣ is involved in atherosclerotic progression from the initial stages of intimal thickening to the subsequent vessel occlusion. 69 It stimulates selectin and adhesion molecule expression by endothelial cells, SMCs and macrophages, promoting interaction between endothelium, leucocytes and platelets, thus creating a pro-inflammatory and prothrombotic local environment. These changes magnify the impact of the local vascular injury and enhance plaque formation. TNF-␣ has also been implicated in modulating plaque morphology and is associated with plaque rupture. It stimulates production of MMP-1-9,11 and 13 production in the endothelium, SMCs and macrophages. 67, 70 Locally, within the atheroma, it increases expression of tissue factor, a potent thrombogenic protein, by macrophage-derived foam cells and the endothelial cells. 71 There is ample evidence implicating TNF-␣ in PAD progression ( Table 2) . 10, 42, 47, 49 Osteoprotegerin, another member of the TNF family, has also been associated with PAD severity. 48 Along with CRP and IL-6, TNF-␣ production has also been found to have a significant correlation in atherosclerotic parents and their offspring (STANISLAS cohort), 53 implicating it as an atherosclerotic risk indicator in healthy families. The impact of TNF-␣ on vascular injury in both acute and chronic inflammatory conditions has made it an important therapeutic target. Unfortunately, results allied to TNF neutralization therapies have been inconsistent thus far. Trials using TNF-␣ antagonist, such as infliximab (ATTACH trial) 72 and etanercept (RENNAISANCE and RECOVER trials), 73 failed to show any improvement in cardiac failure, while the ATTACH trial was associated with an increased allcause mortality. Although there have been no studies focusing on anti-atherogenic therapeutic interventions in PAD, a recent study by DePalma and co-workers, 42 indicated that there were no marked differences in TNF-␣ levels in PAD patients receiving/not receiving statin therapy.
The chemokine family
Chemokines are a large superfamily of small proteins that direct leucocytes to sites of inflammation and can be broadly classified into three distinct groups on the basis of structure and function: CC (e.g. monocyte chemoattractant protein-1), CXC (e.g. IL-8) and CX3C (e.g. fractalkine) chemokine families. MCP-1 and IL-8 are both pro-inflammatory cytokines and contribute to atherogenesis by mediating monocyte/ neutrophil-endothelial interactions.
MCP-1
MCP-1 is the most widely studied chemokine in PAD and it is consistently expressed in both animal and human atherosclerotic plaques. This atherogenic cytokine plays a crucial role in monocyte recruitment into the vascular lesion, which is one of the earliest steps in atherogenesis. While sub-endothelial migration of monocytes is facilitated by engagement of this cytokine with its receptor (CCR2), this interaction is only necessary to allow entry of monocytes into the intima and does not play a significant role in the subsequent macrophage action. 74 There is a plethora of data from mouse studies clearly demonstrating the role of MCP-1 and its receptor in modulation of the atherosclerotic process. 75 MCP-1 has also been found to enhance SMC proliferation by stimulating binding activity of activator protein-1 and promotes expression of integrins and tissue factor on SMCs, generating a pro-inflammatory and a pro-thrombotic environment.
Recently, the ARIC study 46 found MCP-1 to be an independent risk factor for PAD and reported significantly higher levels of MCP-1 in the PAD population. Incidental coronary heart disease was also found to increase significantly in association with MCP-1 levels. Another study correlated MCP-1 levels with the severity of PAD, as assessed by angiographic scores and maximal treadmill walking distance. 41 Consequently, MCP-1 has been suggested as a novel potential target for atherosclerotic therapy. Indeed, statins have been found to have an independent effect on reducing MCP-1 levels. 76 In this respect, administration of 20 mg simvastatin/day can reduce MCP-1 levels by 7% from baseline in hypercholesterolaemic patients. 77
IL-8 (CXCL8)
First described in 1987, IL-8 is probably one of the best characterized neutrophil chemoattractants consistently found in macrophage-rich atherosclerotic plaques. 78 It enhances all aspects of endothelial-neutrophil interaction and migration, facilitating neutrophil recruitment at the site of the vascular inflammation. IL-8 also triggers firm adhesion of rolling monocytes to vascular endothelium and infiltration of the vessel wall, and is thus implicated in early atherosclerotic progression. 79 Mice deficient in IL-8 receptor show decreased macrophage clustering in the plaque and smaller atherosclerotic lesions. 80 A Japanese study involving tissue sampling from human abdominal aortic aneurysms and carotid artery stenoses showed significantly increased expression of IL-8 and its receptor (CXCR2), implicating this chemokine in both aneurysmal and atheroocclusive disease processes. 81 The role of IL-8 in destabilizing the atherosclerotic plaque has been a subject of close scrutiny because of its inhibitory effect on tissue inhibitor of metalloproteinase (TIMP)-1 expression in macrophages, which leads to a consequent increase in MMP activity. 82 Furthermore, the potentially detrimental effects of IL-8 may be compounded by its effects on SMC proliferation. While IL-8 has been associated with unstable angina and acute myocardial infarction, 83 there are some studies addressing its role in PAD. Kirk et al. 52 indicated that significantly higher levels of IL-8 were detectable in PAD patients compared with controls, both at rest and post-exercise. However, this observation was not reproduced in the study of Danielsson et al. 47 which compared the cytokine profiles of PAD patients with/without diabetes and controls.
The IL-10 family IL-10 IL-10 was initially described as a cytokine synthesis inhibitory factor because of its ability to directly inhibit Th 1 and Th 2 cytokine production. This role makes it one of the key regulators of both local and systemic inflammatory/immune responses, and it has been shown to confer a protective effect in atherosclerosis. This is illustrated by the study of Mallat and co-workers, who demonstrated that IL-10-deficient mice fed an atherogenic diet had a threefold increase in lipid accumulation compared with their wild-type counterparts. 84 The plaques in the study group were also more vulnerable and had increased thrombogenic tendencies. Furthermore, Namiki et al showed that intramuscular IL-10 gene transfer significantly reduced the atherosclerotic plaque area in such mice, with an associated decline in IL-12 and IFN-␥ mRNA expression in the spleens of the study group animals. 85 IL-10 is produced by a variety of inflammatory cells and is found in advanced atherosclerotic plaques where it has been associated with decreased apoptosis in the lipid central core, thereby reducing the likelihood of rupture. 86 Systemic and intralesional delivery of IL-10 has been shown to diminish atherosclerosis in a variety of experimental models. 87 One of the reasons for this effect could be a reduction in inflammatory cell recruitment within the plaque: IL-10 has been shown to inhibit monocyte adherence to human aortic endothelial cells in vitro. 88 The ability of IL-10 to suppress certain CD40/CD40L ligand-mediated monocyte responses may account for some of its anti-atherogenic effects, 89 while others may be mediated indirectly through a suppression of pro-inflammatory cytokine (e.g. MCP-1, IL-6, IL-12 and IFN-␥) secretion.
Data regarding the role of IL-10 in PAD in humans are surprisingly scant. It is difficult to determine whether higher or lower IL-10 levels are to be expected as these will vary according to the timing of onset of the disease. On one hand, lower IL-10 levels in PAD would favour disease progression. On the other, higher levels might be expected as a modulatory phenomenon to the associated increase in local inflammatory burden. This complex relationship has been illustrated in coronary artery disease patients, where lower IL-10 levels coupled with higher proinflammatory cytokine levels were observed in patients with unstable angina who subsequently developed a cardiovascular event. 90, 91 Conversely, higher IL-10 levels have been associated with a favourable prognosis in patients with acute coronary syndromes (CAPTURE trial). 92 As such, this suggests that IL-10 may have poor predictive merit for clinical outcome in atherosclerosis. In this respect, the ratio between IL-10 and various pro-inflammatory cytokines may prove more useful as they account for some of the dynamics of the inflammatory processes involved. While IL-10 levels have also been consistently found to be elevated in association with abdominal aortic aneurysms, 93 DePalma et al 49 found IL-10 to be significantly lower in PAD. These findings were resonated by the large InCHIANTI study, which pointed to a marked trend for circulatory IL-10 concentrations to be lower in patients with PAD. 11
The transforming growth factor (TGF) family
TGF-␤ ␤
The TGF family of growth, differentiation and morphogenic glycosylated preproteins comprises of over 50 members. TGF-␤ is both the prototype member of this superfamily as well as one of the most studied cytokines in vascular biology due to its role in atherosclerosis and neo-intimal hyperplasia. Following the work done by Metcalfe and Grainger in the mid-1990s, TGF-␤ is considered to be beneficial in atherosclerosis, leading to the so-called 'protective cytokine' hypothesis. 94 Although this hypothesis was initially postulated based on the role of TGF-␤ in inhibiting vascular smooth muscle cell (VSMC) proliferation and migration, its other immunomodulatory effect on T-cell regulation both within and outside the plaque, 95 and inhibition of pro-inflammatory cytokine (IL-6, granulocyte colony stimulating factor and MCP-1) gene expression 96 gave further momentum to this concept. Whilst inhibition of VSMC proliferation is consistent across studies, the effects of TGF-␤ on macrophages and cytokine inhibition is variable and governed by the local inflammatory environment. 97, 98 As for many other cytokines, most of the initial evidence regarding the anti-atherogenic properties of TGF-␤ was drawn from studies using knockout mice. However, TGF-␤-deficient mice died shortly after birth due to systemic inflammation associated with leucocytic infiltration in virtually every organ system, 99 highlighting the anti-inflammatory effects of TGF-␤ by down-regulation of CAM expression and the consequent reduction in leucocyte infiltration. Studies using heterozygous mouse models proved equally informative, as these animals presented with reduced rather than absent TGF-␤ profiles. Exposing these mice to a high-fat diet enhanced endothelial activation and arterial lipid deposition compared with controls. 100 In line with these observations, Mallat et al noted that inhibition of TGF-␤ signalling is also associated with accelerated atherosclerotic lesion development in apoE-deficient mice and favours the development of those with an increased inflammatory component and decreased collagen content. 101 A related study further showed that TGF-␤ has a definitive role in influencing plaque morphology, with more vulnerable plaques formed in the case of TGF-␤ deficiency due to decreased fibrosis, increased plaque inflammatory cell counts, greater areas of rupture and increased intraplaque haemorrhage. 102 The anti-atherosclerotic role of TGF-␤ is supported by the negative correlation between its plasma levels and coronary artery disease, 103 with similar trends also noted in association with PAD in the InCHIANTI study. 11 These findings suggest that together with IL-10, TGF-␤ may have anti-atherogenic properties which may prove useful in a therapeutic setting.
Conclusion
There are multiple regulatory levels of vascular inflammation with direct or indirect involvement of cytokines at every step. Traditional risk factors such as smoking, hypertension, diabetes, obesity and high cholesterol levels -though useful in population studies -fail to explain the variable nature of disease progression between individuals. Although cytokines are clearly implicated in the pathophysiology of atherosclerosis, there is currently scant information of their role in PAD in particular. However, early evidence in human studies indicates that markers such as IL-6 are closely associated with disease manifestation. Given the intimate interrelationships between cytokines in physiological immune/inflammatory networks, this argues in favour of the case that other cytokines whose role has not yet been implicated in cardiovascular pathophysiology are very likely to also play a role (and likely above and beyond the conventional Th 1 :Th 2 dichotomy). This postulate is further supported by the animal studies reviewed herein.
The findings summarized in this review substantiate the role of cytokines in atherosclerosis and highlight the differences in cytokine responses in different subcatergorizations of atherostenotic or atheroaneurysmal disease processes. As proteins involved in the pathophysiological process per se, cytokines have the potential to provide useful information on disease progression on an individual basis and serve as valuable adjuncts to existing clinical screening and investigative tools in forming a composite picture. Also, the potential role of cytokines in gauging the response to the medical treatment (e.g. statins, aspirin) of atherosclerosis needs to be investigated through larger longitudinal clinical trials. Only then would we be in a position to assess the merit of cytokines as clinical risk stratification tools in cardiovascular medicine.
